Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Neuropharmacology. 2011 May 27;61(4):753–760. doi: 10.1016/j.neuropharm.2011.05.021

Figure 5. Intracortical ±8-OH-DPAT reduces established ALO AIMs.

Figure 5

Sixty min after systemic injections of L-DOPA + Benserazide (12 + 15 mg/kg, sc), VEH or ±8-OH-DPAT (DPAT; 5 & 20mM) were infused continuously into M1 for 60 min using microdialysis. Graphs depict the treatment means for (A) ALO AIMs ± S.E.M., as well as (B) Rotations ± S.E.M. for 6-OHDA-lesioned rats over 3 h of observation. Horizontal white (aCSF) and gray (treatment) bar across graph represents the timecourse of intra-M1 infusion. Treatment effects were analyzed with Kruskal-Wallis ANOVAs and two-way ANOVAs for Rotations. Post hoc comparisons denote significant differences between treatments at the time points indicated (*p < 0.05 for DPAT20 vs. VEH; +p < 0.05 for DPAT20 vs. DPAT5).